Rafael López Castro

Author

Rafael López Castro

Hospital Clínico Universitario de Valladolid ORCID

Also Known As

Castro, Rafael, López-Castro, R., R Lopez, R López, R López Castro, R López-Castro, R. Castro, R. L??pez, R. Lopez, R. Lopez Castro

219

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico Universitario de Valladolid Institut Català d'Oncologia Hospital Universitario Insular de Gran Canaria Hospital General Universitario De Valencia Complexo Hospitalario Universitario A Coruña

About

Rafael López Castro is an author at Hospital Clínico Universitario de Valladolid specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	323
2	Health Sciences	4	4	108
3	Public Health	1	1	30
4	Biostatistics	1	1	25
5	Diagnostic Sciences	1	1	15

Rafael López Castro

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer Mariano Provencio, Ernest Nadal, J.L. González-Larriba, New England Journal of Medicine	2023	397
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, Annals of Oncology	2020	265
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) Josep M. Piulats, Enrique Espinosa, Luis de la Cruz‐Merino, Journal of Clinical Oncology	2021	224
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05) Ernest Nadal, Delvys Rodríguez‐Abreu, Marta Simó, Journal of Clinical Oncology	2023	93
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) Mariano Provencio, Enric Carcereny, Delvys Rodríguez‐Abreu, Translational Lung Cancer Research	2019	86
Lung cancer symptoms at diagnosis: results of a nationwide registry study Alberto Ruano‐Raviña, Mariano Provencio, Virginia Calvo, ESMO Open	2020	73
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Sanjay Popat, Alessandra Curioni‐Fontecedro, Varvara Polydoropoulou, Annals of Oncology OncologyPhase Iii TrialClinical TrialsPleural DiseaseEtop 9-15	2019	54
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations Mariona Riudavets, Édouard Auclin, Miguel Mosteiro, European Journal of Cancer MedicinePathologyCancer GenomicsBronchial NeoplasmDurvalumab Consolidation	2022	52
Lung cancer patients with COVID-19 in Spain: GRAVID study Mariano Provencio, José María Mazarico Gallego, Antonio Calles, Lung Cancer	2021	39
Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962) J.M. Piulats Rodriguez, Luis de la Cruz‐Merino, Enrique Espinosa, Annals of Oncology	2018	33

Page 1